Want to join the conversation?
Canadian pharmaceutical $VRX reported a wider 2Q16 loss due to decline in product sales from existing business and negative foreign currency exchange impact. Net loss widened to $302.3MM or $0.88 per share from $53MM or $0.15 per share last year. Revenues fell to $2.42Bil from $2.73Bil. Adjusted EPS decreased to $1.40 from $2.14.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?